+0.020 (+0.15%)
Range 13.630 - 13.670   (0.29%)
Open 13.630
Previous Close 13.630
Buy Price 13.650
Buy Volume 11
Sell Price 13.660
Sell Volume 10
Volume 461,021
Value -
Measurement Type Value
EPS (USD) -13.554
Trailing EPS (USD) -7.608
NAV (USD) 7.226
Cash In Hand (USD) 2.856
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 1.886
Price / Cash In Hand 4.773
Issued & Paid-up Shares 34,502,700
Treasury Shares -
Market Cap (M) 470.272
Par Value (USD) n.a.
Beta - 75 Days 0.253
R-Squared - 75 Days(%) 0.1
Beta - 500 Days 0.744
R-Squared - 500 Days(%) 7.64
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 23 Oct 2020 02:07.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 29 Oct 2020
View All Events


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turns, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. Its principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). It markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD.

Loading Chart...